Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Leidschendam – page 127

1 919 clinical trials in Leidschendam, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Leidschendam at a glance
1 919
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 919 trials in Leidschendam

Open in trial search

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:PTC Therapeutics Inc.

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Polycythaemia vera

Not recruiting

Study on the Effects of Rusfertide (PTG-300) for Patients with Polycythemia Vera

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rusfertide
  • Sponsor:Takeda Development Center Americas Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Leidschendam

What the registry says about research in the country

01 Oncology - Lung Cancer Research

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatment advancements, evaluating novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • Advanced NSCLC treatments
  • Immunotherapy combinations
  • KRAS G12C inhibitors

Studies compare various treatment options to improve patient outcomes and survival rates.

02 Breast Cancer Studies

Comprehensive research into breast cancer treatments, particularly focusing on hormone receptor-positive and HER2-positive subtypes, investigating targeted therapies and chemotherapy combinations.

  • Metastatic breast cancer
  • HER2-positive therapy
  • Triple-negative breast cancer

Trials examine innovative treatment strategies and personalized approaches.

03 Hematologic Malignancies

Studies focusing on lymphoma treatments, including both Hodgkin and non-Hodgkin variants, evaluating response-adapted therapies and novel drug combinations.

  • Advanced Hodgkin Lymphoma
  • Follicular Lymphoma
  • Treatment optimization

Research aims to improve treatment outcomes while minimizing toxicity.

04 Gastrointestinal Oncology

Investigations into colorectal cancer and related conditions, including innovative surgical approaches and treatment strategies for recurrent disease.

  • Rectal cancer treatments
  • Esophagogastric cancer
  • Surgical innovations

Focus on improving surgical outcomes and treatment effectiveness.

05 Brain Metastases Research

Studies examining treatment options for cerebral radiation necrosis and brain metastases, including innovative detection methods and therapeutic approaches.

  • Radiation necrosis treatment
  • Metastatic detection
  • Targeted therapies

Research aims to improve detection and treatment of brain metastases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.